327 related articles for article (PubMed ID: 32094155)
1. Advances in Targeting RET-Dependent Cancers.
Subbiah V; Cote GJ
Cancer Discov; 2020 Apr; 10(4):498-505. PubMed ID: 32094155
[No Abstract] [Full Text] [Related]
2. State-of-the-Art Strategies for Targeting
Subbiah V; Yang D; Velcheti V; Drilon A; Meric-Bernstam F
J Clin Oncol; 2020 Apr; 38(11):1209-1221. PubMed ID: 32083997
[TBL] [Abstract][Full Text] [Related]
3. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract][Full Text] [Related]
5. Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
[TBL] [Abstract][Full Text] [Related]
6. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
7. Hallmarks of RET and Co-occuring Genomic Alterations in
Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
[TBL] [Abstract][Full Text] [Related]
8. RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A; Miranda-Morales E; den Hollander P; Friedlaender A; O Sintim H; Wu J; Mani SA; Subbiah V
Pharmacol Ther; 2023 Feb; 242():108344. PubMed ID: 36632846
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.
Drosten M; Pützer BM
Nat Clin Pract Oncol; 2006 Oct; 3(10):564-74. PubMed ID: 17019434
[TBL] [Abstract][Full Text] [Related]
10. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX; Li QQ; Cai J; Wu JZ; Wang JJ; Zhang MY; Wang QX; Tong ZJ; Yang J; Wei TH; Zhou Y; Dai WC; Ding N; Leng XJ; Sun SL; Xue X; Yu YC; Yang Y; Li NG; Shi ZH
J Med Chem; 2024 Mar; 67(6):4346-4375. PubMed ID: 38484122
[TBL] [Abstract][Full Text] [Related]
11. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract][Full Text] [Related]
12. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
Erickson TA; Shih YP; Fass J; Jang M; Tran E
Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
[No Abstract] [Full Text] [Related]
13. REToma: a cancer subtype with a shared driver oncogene.
Kohno T; Tabata J; Nakaoku T
Carcinogenesis; 2020 Apr; 41(2):123-129. PubMed ID: 31711124
[TBL] [Abstract][Full Text] [Related]
14. Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.
Li T; Yang WY; Liu TT; Li Y; Liu L; Zheng X; Zhao L; Zhang F; Hu Y
Technol Cancer Res Treat; 2023; 22():15330338221148802. PubMed ID: 36628459
[TBL] [Abstract][Full Text] [Related]
15. Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.
Dabelić N; Jukić T; Fröbe A
Acta Clin Croat; 2020 Jun; 59(Suppl 1):50-59. PubMed ID: 34219884
[TBL] [Abstract][Full Text] [Related]
16. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes.
Drilon A; Hu ZI; Lai GGY; Tan DSW
Nat Rev Clin Oncol; 2018 Mar; 15(3):151-167. PubMed ID: 29134959
[TBL] [Abstract][Full Text] [Related]
17. Targeting RET alterations in cancer: Recent progress and future directions.
Shabbir A; Kojadinovic A; Shafiq T; Mundi PS
Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304
[TBL] [Abstract][Full Text] [Related]
18. Landscape of Acquired Resistance to Osimertinib in
Piotrowska Z; Isozaki H; Lennerz JK; Gainor JF; Lennes IT; Zhu VW; Marcoux N; Banwait MK; Digumarthy SR; Su W; Yoda S; Riley AK; Nangia V; Lin JJ; Nagy RJ; Lanman RB; Dias-Santagata D; Mino-Kenudson M; Iafrate AJ; Heist RS; Shaw AT; Evans EK; Clifford C; Ou SI; Wolf B; Hata AN; Sequist LV
Cancer Discov; 2018 Dec; 8(12):1529-1539. PubMed ID: 30257958
[TBL] [Abstract][Full Text] [Related]
19. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
20. Targeting of RET oncogene by naphthalene diimide-mediated gene promoter G-quadruplex stabilization exerts anti-tumor activity in oncogene-addicted human medullary thyroid cancer.
Lopergolo A; Perrone R; Tortoreto M; Doria F; Beretta GL; Zuco V; Freccero M; Borrello MG; Lanzi C; Richter SN; Zaffaroni N; Folini M
Oncotarget; 2016 Aug; 7(31):49649-49663. PubMed ID: 27351133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
